Resolve Therapeutics raises $2M to advance early lupus candidate
This article was originally published in Scrip
Executive Summary
Resolve Therapeutics LLC, based in Seattle, Washington, has raised $2 million in a Series A round to support the development of the company's lead candidate, RSLV-125, for lupus, which is in preclinical testing. Additional research is underway with the molecule and the company says that it expects to begin human clinical studies in the near future.